Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of ACYW135 Meningococcal Conjugate Vaccine in Children
NCT06337071Phase 2Not yet recruiting
- Sponsor
- AIM Vaccine Co., Ltd.
- Start
- Mar 2024
- Primary completion
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of meningococcal group A, C, Y and W135 conjugate vaccine in meningococcal meningitis, sponsored by AIM Vaccine Co., Ltd.. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
meningococcal group A, C, Y and W135 conjugate vaccine
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT06337071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06337071.